The Low DoseThe GLP-1 price desk
Briefing

PlexusDx vs Coby Health

$189/mo against $239/mo for tirzepatide. Which is worth it, and for whom.

Illustration of two objects on a balance scale

Updated 2026-09-18

Both sell tirzepatide. PlexusDx costs $189 a month and Coby Health costs $239, a difference of $50 a month or about $600 a year. The desk reads it as follows.

PlexusDx is pharmacy transparency and genetic testing. Coby Health is multi-month value with supplies included. They are not aimed at the same person, and the cheaper one is not automatically the right answer — though on this board it usually is.

Advert against bill. PlexusDx advertises $129 and bills $189; Coby Health advertises $179 and bills $239. Both gaps are the same size, so the advertised comparison happens to hold.

Side by side

PlexusDxCoby
Advertised$129$179
Billed$189$239
Gap+$60+$60
Per year, billed$2,268$2,868

Prices verified 2026-09-18. "True monthly cost" is what you are billed in month two, once any introductory rate has lapsed and any membership has renewed.

The split

3 differences on the record. The others match.

PlexusDxCoby
Price is the same at every doseYesNo
Names the compounding pharmacy publiclyYesNo
Offers an oral or sublingual optionYesNo

What each puts on the record: PlexusDx

  • No membership or platform fee is charged alongside the medication.
  • Publicly names six 503A pharmacy partners: Belmar, Strive, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub and Foothills.

Where it wins: The most detailed pharmacy disclosure in this comparison — six named 503A partners. Watch for: The advertised "from $129" is the programme floor. Budget $189/month for the compounded injection tier.

What each puts on the record: Coby Health

  • Monthly plans can be cancelled at any time.
  • States plainly on its own product pages that compounded medication is not FDA-reviewed or approved.

Where it wins: Injection supplies are included rather than something you source yourself. Watch for: The $179 figure is a multi-month rate. Month-to-month is $239.

In each one’s favour

PlexusDx.

  • The most detailed pharmacy disclosure in this comparison — six named 503A partners.
  • Names its prescribing physicians along with their NPI numbers.

Coby Health.

  • Injection supplies are included rather than something you source yourself.
  • Monthly plan is genuinely cancel-anytime.

PlexusDx scores higher overall at 4.4 out of 5. The weights are published on how we rate, and so is the note about which of these is our paid featured partner.

The desk’s call

The board says PlexusDx. What the board cannot say is whether the advertised figures you were shown elsewhere match these — check the gap row, because a listing that advertises low and bills high will beat an honest one in any comparison built on advertised prices.

The verdict

On the board, PlexusDx at $189 a month is the more defensible choice on arithmetic alone. Coby Health earns its premium only if you will actually use what it does differently. Read the full reviews before deciding: PlexusDx and Coby Health.

How they sit against everyone else

ProgrammeAdvertisedBilledGapVs board floor
Coreage Rx$149$199+$50+$74/mo
Trimi$125$125none—
Ozari Health$125$125none—
Fifty 410$133$133none+$8/mo

More from the desk

  • PlexusDx tirzepatide review

    Advertised at $129, billed at $189. Position 5 of 18 on our board.

  • Coby Health tirzepatide review

    Advertised at $179, billed at $239. Position 9 of 18 on our board.

  • How to spot a bad seller

    The FDA sent more than 55 warning letters to online GLP-1 sellers in one day. Here is how to tell a licensed programme from the rest.

  • The twelve-month cost

    Month one is the cheapest month you will have. Here is the full-year arithmetic, including the costs nobody puts in the advert.

  • Cheapest right now

    Every programme sorted on what it bills, not what it advertises. Floor: $199/mo tirzepatide, $149/mo semaglutide.

Coreage Rx pays us a commission on sign-ups through our links. It does not affect our scores or rankings. How we rate · Disclosure